Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Advisors Will Ponder Sandoz’ Pegfilgrastim And Pfizer’s Trastuzumab

Executive Summary

A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.

You may also be interested in...



Mylan And Biocon Introduce Fulphila In Australia

Mylan and Biocon have launched their Fulphila biosimilar version of pegfilgrastim in Australia, marking the pair’s third local biosimilar launch under their partnership.

MSD’s Ontruzant Gets Australian Reimbursement

Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.

Australian Price Cuts Keep On Coming

Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel